Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 101Recruiting 60Active not recruiting 52Unknown 22Terminated 20Not yet recruiting 18Withdrawn 7

Sponsor Class

OTHER 4INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 6Tumor-Agnostic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 5Sarcoma 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1HER2-positive Breast Cancer 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Withdrawn × Interventional × pertuzumab × Clear all
NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

University of Rochester

Phase 2 Withdrawn
Breast

HER2-positive Breast Cancer

NCT06884254 2025-10-14

EGC102

EirGenix, Inc.

Phase 3 Withdrawn
Breast

Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02336984 2021-01-11

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Withdrawn
Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT03811418 2019-11-26

ATTILA

iOMEDICO AG

Phase 3 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT03058939 2019-04-22

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

University of Chicago

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡